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Foreword 
 
In developing its future programme of grant-funded research, Alcohol Change UK wished 
to explore what is known, and what is yet to be understood, in a series of key areas, as 
follows: 
 
Topic one The role of alcohol in intimate partner relationships 
 
Topic two The impact of alcohol on the human brain 
 
Topic three Alcohol interventions and the criminal justice system 
 
Topic four The relationship between alcohol and mental health problems 
 
Topic five Drinking problems and interventions in black and minority ethnic 
communities 
 
Topic six Digital interventions to reduce alcohol-related harm 
 
These areas were selected through stakeholder engagement and consultation, as well as 
‘horizon-scanning’ the research, policy and practice environment to identify where 
particular gaps appeared.  
 
Rapid evidence reviews were commissioned on the six topics and their findings will allow 
Alcohol Change UK to synthesise knowledge on this particular range of subjects. This will 
help inform its own work, as well as leading to outward-facing publications that will allow 
the public, practitioners and policy-makers to better understand the research in these key 
areas.  
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Executive summary 
 
Background 
 
The relationship between mental health disorders and alcohol misuse is complex, with 
the potential for multiple variations of diagnoses and mutually dependent problems 
(Baigent, 2012). There is a level of inconsistency in the definitions of comorbid mental 
health and co-occurring substance use disorders including Alcohol use Disorders (AuDs). 
In addition, there are multi-faceted and complex associations between AuDs and the 
various psychiatric disorders and these relationships are nuanced in terms of direction 
and symptomology.  The term ‘dual diagnosis’ implies that there are only two clinical 
problem areas when in fact there are usually several, all of which are specific to the 
individual and manifest in varying and multiple combinations. These may include a range 
of domains, including personal, familial and social, physical health, mental and emotional 
health, involvement in the criminal justice system and accommodation. Therefore, it may 
be more useful to conceptualise this group as having ‘complex needs’ and subsequently 
reflect on working models and strategies which are flexible and tailored to the needs of 
the individual.  
 
The high prevalence of coexisting mental health and substance use problems within 
mental health services is recorded in a number of studies in the United Kingdom (UK). 
The rates of co-occurring disorders recorded within UK mental health and addiction 
services vary between 30 and 85% (Schulte, 2008; Weaver et al., 2003; NICE, 2016) 
Evidence from a National Institute for Health and Care Excellence (NICE) review of 
prevalence of co-occurring conditions across secondary mental health settings indicated 
that the prevalence rate of co-occurring disorders was 34.3%, although due to 
heterogeneity of the sample it was stated that the result should be treated with caution 
(NICE, 2016).  In order to respond to the myriad of problems engendered by comorbid 
AuDs and mental health disorders, a combination of service models have been 
developed in the UK and on an international basis. The majority of models of service 
delivery can be categorised as serial, parallel or integrated with the latter viewed as the 
most beneficial for service users and patients. Furthermore, interventions are also 
characterised by the many and varied range of pharmacological and psychosocial 
treatment modalities. Therefore, this review sought to provide an overview of policy, 
service delivery and treatment models to consider the context of treatment and the 
effectiveness of interventions relevant to individuals with comorbid conditions.  
 
Aims  
 
The Rapid Evidence Assessment (REA) considered two primary research aims: 
 
1 To examine the effectiveness of psychosocial and pharmacological interventions for 
adults (18+) with comorbid alcohol use and mental health problems. 
2 To identify the general policy framework for co-occurring substance use disorders and 
Alcohol Use Disorders (AuDs), assessment models, care plans and guidelines for 
practice within the UK. In addition, there was a specific focus on models of treatment 
delivery within the UK and international contexts. 
 
Methods 
 
 
 
2 
A dualistic approach to the review was employed in accordance with the two primary 
aims of the review. First, a rapid review employing a systematic approach to searching, 
appraising and reviewing the results was used to identify the evidence base as regards 
interventions for comorbid alcohol use disorders and mental health disorders. Second, 
there was a broad literature review of UK policy frameworks and guidance documents 
which considered assessment and care planning and models of treatment service 
delivery in the UK. The section was augmented with international literature from the 
United States and European sources. 
 
Findings 
 
Findings suggest that there is a strong association between AuDs and mental health 
disorders including: depression, anxiety, bipolar disorder, personality disorder and 
schizophrenia. Across the UK, the policy framework for substance use disorders and 
mental health comorbidity is inconsistent and is even more fragmented as regards 
alcohol-specific co-occurring disorders. In England, the last comprehensive guide to 
policy and practice was published by the Department of Health in 2002; whilst in Northern 
Ireland there has been a gap in specific policy guidance for comorbid substance use and 
mental health disorders since 2005. However, the Welsh government produced a recent 
comprehensive policy framework which addressed the specific needs of people with 
comorbid disorders in 2015. Similarly, Scotland may not have a recent specific policy 
framework document related to comorbidities but it does make a substantial reference to 
comorbid disorders in a number of mental health and alcohol policy frameworks 
(Scotland Mental Health Strategy 2017-2027, Scottish Government 2018, Alcohol 
framework, 2018).   
 
According to the evidence, all levels of assessment and care planning in working with 
comorbid disorders must be tailored to the complex individual needs of the service user 
(and carers where appropriate), be developed in full partnership with the service user 
(where possible) and founded on a non-judgemental, empathic and person-centred 
approach. In addition, shunting of service users between mental health and substance 
disorder services is often apparent with a lack of clarity about case management 
responsibility.  NICE (2016) guidance also recommends that initial goals for alcohol and 
mental health comorbidities may be agreed on the basis of a harm reduction approach 
but that the ultimate goal for this specific service user grouping should be abstinence. 
 
Three models of service delivery were identified from the literature: serial, parallel and 
integrated. Whilst the integrated service model demonstrates more efficacious treatment 
outcomes (Mangrum et al., 2005; Muser et al., 2003; McCoy et al., 2003), it is not entirely 
clear how many treatment providers in the UK currently provide an integrated service for 
concomitant AuDs and mental health disorders.  However, there is the suggestion that 
the majority of treatment models in the UK and the United States tend to work within the 
parameters of the serial and parallel models.  In Europe, there is substantial 
heterogeneity in the range of treatment models offered for co-existing disorders, although 
it is noted that the wide range of options may also act as barrier to treatment provision as 
some providers may lack the skills and expertise to address the needs incurred by both 
AuDs and mental health disorders. 
 
Results from the current rapid structured review of interventions for alcohol use 
problems/disorders and comorbid mental health conditions showed mixed results for both 
pharmacological and psychosocial intervention studies. Naltrexone was the most 
commonly administered pharmacological intervention, and was most beneficial when 
combined with other drugs (for example Sertraline and Disulfiram) than when used alone. 
The combination was successful at treating alcohol use and psychiatric symptoms 
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compared to placebo (Petrakis et al., 2005, Pettinati et al., 2011).  Similar to Naltrexone, 
when Sertraline was used alone it was less successful at treating comorbid conditions 
(Gual et al., 2003). In addition, combinations of lorazepam and Dilsulfiram demonstrated 
promising outcomes with reductions in alcohol use and psychiatric symptoms.  
Conversely, single application of Acamprosate was reported to be the least effective in 
the treatment of comorbid conditions (Tolliver et al., 2012; Ralevski et al., 2011). Whilst 
the majority of the studies were randomised controlled trials (RCTs), there was some 
evidence of methodological design flaws, including lack of appropriate control groups, 
small sample sizes and high attrition rates. 
 
Cognitive behavioural therapy (CBT) was reported as an effective psychosocial 
intervention in treating at least one aspect of comorbid problematic alcohol use and 
psychiatric conditions (Toneatto & Calderwood, 2015; Morely et al., 2016; Brown et al., 
2011). Moreover, computer-based CBT outcomes were similar, if not more effective than 
therapist-based CBT for a reduction in depressive symptoms and alcohol use (Agyapong 
et al., 2013; Deady et al., 2016; Kay-Lambkin et al., 2008) and a non-significant reduction 
in alcohol-related problems only (Geisner et al., 2016). On the other hand, outcomes 
from a motivational interviewing (MI) based intervention were not significantly different 
when compared to a ‘brief advice’ intervention. However, both groups experienced 
improvements in comorbid conditions. Only one study reported a specific integrated 
intervention administrating a pharmacological agent and psychosocial support.  Although 
it reported a small sample and no control or comparison group, Lamotrigine and an 
individual relapse prevention programme demonstrated a significant reduction in 
problematic alcohol use and psychiatric symptoms.  
 
Conclusion 
 
Results from both the policy/guidance and interventions components of the review 
indicate the complex issues and the problems faced by vulnerable individuals who have 
comorbid AuDs and mental health disorders. It is clear that the multi-faceted problems 
reach far beyond the dual diagnosis label to include many and varied combinations of 
mental and physical health problems.  National and regional UK Governments have tried 
to address some of the complex and multi-layered issues via a number of policy 
framework and guidance documents. The somewhat sporadic UK Government 
documentation on co-occurring disorders has been usefully supplemented by published 
material from expert commentators, practitioners and community-based or voluntary 
sector mental health and substance use disorder organisations. From the policy review, it 
is clear that the development of a UK national policy framework for working with 
comorbid mental health and substance use disorders is overdue and should specifically 
address the issues of morbidities related to AuDs. In addition, whilst the interventions 
review indicated some level of success for CBT, and other psychosocial and mixed 
modality drug interventions as first line treatment options for comorbid AuDs and mental 
health disorders, it is apparent that the majority of studies are marred by weak research 
design. It is also clear that studies with high-quality design and rigorous methodological 
approaches should be developed to examine the efficacy of pharmacological, 
psychosocial and integrated treatments for comorbid disorders.  
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Introduction 
  
The nature and prevalence of co-occurring alcohol use disorders and mental health 
conditions is increasing within mental health and substance use disorder services. 
Moreover, the concomitant problems for individuals, families and communities are 
becoming ever more complex and the absence of a coordinated approach in some 
regions of the UK are further exacerbating poor outcomes for patients and service users. 
The relationship between mental health disorders and alcohol misuse is complex, with 
the potential for variable combinations of diagnoses and mutually dependent problems 
(Baigent, 2012). Staff working in psychiatric and addiction service settings frequently 
encounter the challenges involved in treating these patients and balancing the 
management of risk with the promotion of patient empowerment. 
 
One common understanding of dual diagnosis is the presence of comorbid alcohol 
misuse in an individual with at least one psychiatric disorder (WHO, 1995). It is not 
recognised in the diagnostic classifications and so is not considered to be a formal 
psychiatric diagnosis. Definitions can vary with some excluding the most prevalent 
psychiatric conditions in practice, such as anxiety and personality disorders (Marshall & 
Farrell, 2006; Drake, 2007). To complicate matters further, both psychiatric and alcohol 
use disorders have their own spectrum of severity and diagnostic classification (Chrome 
& Myton, 2004; Thoma & Daum, 2013). This lack of a consistent definition makes 
communication difficult and limits useful comparison of the evidence-base (Canaway & 
Merkes, 2010).The term dual diagnosis implies that there are only two clinical problem 
areas when in fact there are usually several, all of which are specific to the individual and 
manifest in varying and multiple combinations. These may include inter-related domains, 
for example, personal responsibility, social contact, managing physical health, mental 
and emotional health, daily lifestyle, relations, crime and accommodation. Therefore, it 
may be more useful to conceptualise this group as having ‘complex needs’ and thus 
consider and reflect on working models and strategies which are flexible and tailored to 
the needs of the individual. Due to the range of terms used to define a diagnosis of both 
mental health disorders and alcohol use disorders (AuDs) by authors, expert 
commentators and researchers from a range of health and social care backgrounds, the 
following report will use alternate terminology to describe the complex marriage of a 
range of comorbidities. This will include co–occurring/coexisting disorders, comorbid 
disorders, multiple morbidities and to a lesser extent dual diagnosis as it is now widely 
accepted that the term dual diagnosis is considered inadequate when discussing the 
complexities inherent to combined mental health and AuDs. It is also apparent that the 
diagnosis of both disorders may have originally been associated with combination of 
alcohol disorders and more severe and enduring mental illnesses (SMIs), for example 
schizophrenia and bipolar disorders. However, the recent rise in numbers of complex 
morbidities that are related to AuDs such as anxiety and depressive disorders is reflected 
in the literature and therefore the review considers a range of SMIs including anxiety and 
mild to moderate depressive disorders. 
 
Nature and Prevalence 
 
From the prevalence figures described below, it is clear that alcohol-related harms and 
comorbidities have increased in the majority of the four UK nations. In England, there 
were 337,870 hospital admissions due to alcohol in 2017/18. This figure has not changed 
greatly since 2016/17 although over a ten-year period, it is 15% higher than 2007/2008 
figures (NHS Digital, 2019).  In addition, there were 5,483 alcohol-specific deaths, 6% 
higher than in 2016 (ONS, 2019).  Figures from Wales show that in 2017-18, hospital 
admissions for alcohol-specific conditions were 2.4 times higher than for illicit drug use. 
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There were also 540 alcohol deaths in 2017 which represents an increase of 7.1% from 
2016 (Welsh Government, 2019). Scottish statistics indicate that there 
were 1,265 alcohol-related deaths in 2016, an increase of 10% in comparison with 2015.  
Furthermore, there were 36,235 alcohol-related hospital admissions in 2016/17 (NSS, 
2017; NRS, 2019). 
  
The high prevalence of coexisting mental health and substance use problems within 
mental health services is well-documented via recorded prevalence rates in various UK 
studies. The rates of co-occurring disorders recorded within UK mental health and 
addiction services range between 30 and 85% (Schulte, 2008; Weaver et al., 2003; 
NICE, 2016). In a national survey Schulte et al. (2008) estimated that 32% of service 
users who were engaged with mental health and addiction services in England recorded 
a dual diagnosis although almost 50% did not receive assessments for both mental 
health conditions and substance use problems and joint protocols for treatment remained 
unstructured. Delgadillo et al. (2012) found 70% of a sample from community substance 
use treatment were also diagnosed with common mental health disorders. Evidence from 
a NICE review of the prevalence of co-occurring conditions across secondary mental 
health settings (NICE, 2016) highlighted rates of between 11.7% and 61.2% for 
substance use/misuse/dependence within the past year.  A combination of data from nine 
relevant studies indicated that the prevalence rate of co-occurring disorders was 34.3%, 
although due to the heterogeneity it was stated that the result should be treated with 
caution (NICE 2016). In the UK it is estimated that over 33% of psychiatric patients with 
severe and enduring mental illness have a substance misuse problem including an 
alcohol use disorder, whilst over 50% of clients currently accessing drug and alcohol 
services have a mental health problem (University of Manchester, 2015). 
 
Co-occurring Substance use with Specific Mental Health Disorders 
 
Alcohol use disorders (AuDs) are associated with a range of mental health difficulties 
including: depression, anxiety, bipolar disorder, personality disorder and schizophrenia 
(PHE, 2016). In 2014/15, there were 203,700 hospital admissions for mental disorders 
related to alcohol use and this accounted for 19% of hospital admissions in that period in 
the UK (PHE, 2016).  
 
Evidence suggests that there is a causal linkage between alcohol use disorders and 
depression where an increased use of alcohol is positively correlated with an increased 
risk of depression (Boden, 2011; Kuria, 2012; Van den berg, 2014). The association 
between alcohol dependence and depression may be attributable to the depressive 
effects of ethanol and it is widely expected that in this specific comorbidity dyad, 
indicators of depression often lessen or cease with abstinence (Pary & Patel, 2017).  
 
Presentation of dually diagnosed AuDs and anxiety disorders is relatively common and is 
often synonymous with a range of complex factors. Symptoms of anxiety often present as 
a result of withdrawal from a number of substances including alcohol.  Conversely, 
anxiety disorders are a risk factor for the development of substance use disorders and 
may exacerbate the symptomology of a range of anxiety disorders.  Accurate diagnosis 
and care planning requires a person centred and individualised approach to treatment to 
provide the best treatment outcomes for service users. Furthermore, standard 
interventions for anxiety disorders or AUDs may need to be amended and merged in 
ways to accommodate the precise needs of individuals who have the co-occurring 
disorders (Smith & Randall, 2012, Back & Brady, 2008). 
 
The association between schizophrenia and comorbid alcohol disorders has been widely 
acknowledged by service users and practitioners. Alcohol has been reported as having 
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mediating effects on symptoms of the disorder, often precipitating a sedative effect on 
delusional beliefs, emotional blunting, and chaotic thought processes associated with 
schizophrenia. As substance use disorder is often seen in conjunction with a diagnosis of 
schizophrenia (paranoid, disorganised, residual, and undifferentiated) an individual who 
displays symptoms of the illness should also be evaluated for alcohol or drug use or 
dependence (American Centre of Addictions, 2019). There is also some evidence as 
regards the association between AuDs and bipolar disorders with experts purporting that 
alcohol use disorders are also highly prevalent in individuals who have been diagnosed 
with bipolar disorder (Cardoso et al., 2008). In a review by Farren et al. (2012) the 
authors reported that substance use disorders are associated with increased suicidal 
behaviour in people with a bipolar disorder. The risk of attempted suicide is almost 
double for these patients in comparison to bipolar patients who do not abuse alcohol 
(Farren et al., 2012). 
 
Aims of the Review 
 
The Rapid Evidence Assessment (REA) considered two primary research aims: 
 
1 To examine the effectiveness of psychosocial and pharmacological interventions for 
adults (18+) with comorbid alcohol use and mental health problems.  
2 To identify the general policy framework for co-occurring substance use disorders and 
Alcohol Use Disorders (AUDs), assessment models, care plans and guidelines for 
practice within the UK. In addition, there was a specific focus on models of treatment 
delivery within UK and international contexts. 
Methodology  
 
A Rapid Evidence Assessment (REA) method was used to identify, select and analyse 
the literature relevant to this review on mental health and alcohol use/alcohol use 
disorders. REAs provide a rigorous, open and effective means of evaluating what is 
known and are particularly suited to projects where the potential literature is very broad 
but where the themes from the evidence are needed to inform policy direction. The key 
stages of a REA are to develop search strategies and identify appropriate databases, 
screen the results against agreed inclusion criteria, assess the quality of the included 
results, extract the key findings from the included results, and provide a synthesis of the 
key themes to inform the discussion and recommendations of the review. The 
Government Social Research Service and the Evidence for Policy and Practice 
Information and Co-ordinating Centre (2013) recommend a REA when there is a need to 
decide on a policy direction based on the best available evidence but despite there being 
a wide range of literature there are ongoing debates and questions. The current 
methodology was informed by discussion with the Drug and Alcohol Research Network 
(DARN) and The Mental Health Advisory Group members, both based at the School of 
Education and Social Sciences at Queens University Belfast. A dualistic approach to the 
review was utilised according to the primary aims identified above. First, a rapid review 
employing a systematic approach to searching, appraising and reviewing the results was 
used to identify the evidence-base as regards interventions for comorbid alcohol use 
disorders and mental health disorders. Secondly, there was a broad literature review of 
UK policy frameworks and guidance documents which considered assessment and care 
planning, and models of treatment service delivery in the UK. The section was 
augmented with international literature from United States and European sources. The 
key phases of the REA for this review are summarised below. 
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Identifying the literature  
 
Databases  
 
Studies were identified using the following electronic databases: International 
Bibliography of the Social Sciences (IBSS), PsycINFO, Scopus, Social Care Online 
(SCIE), Social Science Citation Index, ERIC and Medline.  
Pertinent national and international drug and alcohol and mental health websites, key UK 
government reports and guideline documents were also accessed to identify policy 
frameworks, guidelines and extant literature relevant to the topics of mental health and 
alcohol use disorders. During searches it became apparent that some significant 
messages, with regards to mental health and alcohol specifically, were embedded in 
policy documents and other reports which considered mental health disorders alongside 
an overview of both alcohol use and drug use.  
 
Search strategy 
 
Search strategies were developed and refined in collaboration with clients, key 
stakeholders and a specialist librarian. The search terms (or similar phrases) included 
‘alcohol misuse’, ‘mental health’, ‘comorbidities’ and ‘intervention’ and were limited to 
publications between January 2002 to May 2019, involving adults and written in the 
English language (see Appendix A for primary search strategy). 
 
Inclusion and Exclusion Criteria 
 
Criteria were compiled according to the two primary aims (see table one). 
 
Table 1: Exclusion and Inclusion Criteria 
Aim One: An examination of psychosocial 
and pharmacological interventions for adults 
with comorbid alcohol use and mental health 
problems. 
Aim Two: Analysis of the policy frameworks, 
care plans and clinical guidelines for practice 
within the UK and models of treatment 
delivery within UK and international contexts. 
 
Inclusion Criteria 
Peer-reviewed Journals 
English Language 
Quantitative and mixed methods research 
Substance / Alcohol use /misuse or disorder 
Mental illness disorder or psychiatric disorder 
Dual Diagnosis / comorbidities /AuDs and 
Mental Health Disorders 
Interventions Psychosocial or pharmacological 
Exclusion 
Participants under 18 years 
Policy or framework document 
 
Inclusion Criteria 
UK government and regional policy 
documents on aspects of the care continuum 
for comorbid conditions 
UK clinical guidelines 
UK and international literature on service 
models of treatment 
 
 
Exclusion 
International policy documents 
International literature on assessment and 
care planning  
 
 
Screening methods 
 
The results of all search strategies for the interventions component of the review were 
imported to the screening tool, Rayyan (Ouzzani et al., 2016). Using clearly defined 
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inclusion criteria, all papers were screened by two members of the research team using 
title and abstract initially. Any disagreements were referred to a third review author in the 
team. Accessible full text copies were then screened by two research team members to 
assess their eligibility for inclusion in the study.   
 
Data extraction 
 
A developed data extraction tool was used to capture all necessary information for the 
intervention review including: (1) type of study (2) participants (3) intervention (4) clinical 
outcomes (5) clinical scales (6) clinical facility (7) timeframe of intervention (8) key results 
(9) limitations (table 2). 
 
Quality appraisal 
 
Quality of interventions evidence was assessed using the Cochrane Risk of Bias Tool 
(CRBT; Higgins et al., 2011) for intervention studies using randomised methodologies 
(see appendix B).  The CRBT has six domains including sequence generation, allocation 
concealment and blinding (personal, participants and outcomes, incomplete data, 
selective outcome reporting and ‘other sources of bias’).  The CRBT is designed to be 
comprehensive in evaluating randomisation and blinding (Armijo-Olivo et al., 2012).  The 
Evidence Project Risk of Bias tool was used to assess studies using non-randomised 
methodologies. The Evidence Project Risk Bias tool (EPRBT) includes five key domains 
including study design (pre-post intervention data, control or comparison group, cohort), 
comparison of groups (comparison groups equivalent on socio-demographics and 
comparison groups equivalent at baseline on outcome measure), sampling (random 
assignment of participants to the intervention, random selection of participants for 
assessment), control for potential confounders and follow up rate of 80% or more.  The 
EPRBT is applicable for pre-post design or cohort studies and can be used without 
adaptation (Kennedy et al., 2019; see appendix B).   
 
Data synthesis 
 
The intervention findings were discussed narratively due to the nature of the outcome 
assessments and quality of reporting for the interventions.  A categorisation of data and 
descriptive summary are provided. The policy documents and frameworks section of the 
review was themed according to the following headings: policy frameworks (UK), 
assessment models (UK), care planning (UK), treatment models (International and UK).    
 
Included evidence 
 
Included studies for Interventions Review  
 
After removing duplicates (n=46), 8,727 articles were identified for title and abstract 
screening.  8,157 articles were later excluded based on title and abstract. The remaining 
570 articles were included for full text screening. Subsequently, 551 articles were later 
excluded, and 19 articles were included for extraction. In addition, reference lists of 
fourteen reviews were examined, identifying a further five studies.  In total, 24 studies 
were included for extraction in this rapid review.  
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Figure 1: Rapid review flow chart  
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Findings  
 
Research Aim One - Review of Interventions 
 
1 To examine the effectiveness of psychosocial and pharmacological interventions for 
adults (18+) with comorbid alcohol use and mental health problems.  
 
Study measures  
 
All studies included participants with comorbid disorders involving an alcohol use 
disorder and mental health disorders.  Studies utilised a wide range of standardised and 
non-standardised measures (n=52). The most common alcohol outcome assessment 
included the Substance Abuse Calendar/Timeline Follow-Back Interview (TFLB; Sobell & 
Sobell, 1992) and the Obsessive Compulsive Drinking scale (OCDS; Anton et al., 1995). 
The most common psychiatric outcome assessment was the Hamilton Depression Rating 
Scale (HAM-D; Bech et al., 1979) and the Brief Psychiatric Rating Scale (BPRS; Overall 
et al., 1962). 
 
Settings 
 
The majority of studies were out-patient based (Rubio et al., 2006; Deady et al., 2016; 
Kay-Lambkin et al., 2008; Morley et al., 2016; Toneatto & Calderwood, 2015; Brown et 
al., 2011; Andrisano-Ruggieri et al., 2016; James et al ., 2004; Brady et al., 2005; Brown 
et al., 2009; Brown et al 2014; Bogenschutz et al., 2016; Di Nicola et al., 2017; Gual et 
al., 2003; Hernandez-Avila et al., 2004; Martinotti et al 2008; Petrakis et al., 2005; 
Pettinati et al., 2010; Ralevski et al., 2011; Tolliver et al.,2012; Salloum et al., 2005) 
which involved health service research departments or addiction clinics based in 
hospitals, psychiatric and community mental health settings.  One study recruited in 
patients within a hospital setting (Baker et al., 2002) and two studies took place in service 
user homes (Ralevski et al., 2011; Agyapong et al., 2013). 
 
Interventions 
 
Twenty-four studies which considered interventions of comorbid conditions were included 
in the rapid review. Three intervention domains were identified: psychosocial, 
pharmacological and integrated drug treatment and psychosocial treatment interventions. 
Ten studies used only psychosocial interventions involving one or more of the following: 
group therapy, motivational interviewing (MI) or cognitive behavioural therapy (CBT). 
Thirteen studies involved only a pharmacological intervention. One study conducted an 
integrated treatment intervention using pharmacological and psychosocial components 
(see table two). 
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Table 2: Studies Included in the Intervention Review 
Authors Design Participants Intervention 
 
Clinical 
Outcomes 
 
Clinical 
Scales 
Clinical 
facility 
 
Timeframe 
 
Results 
 
Limitations 
 
Integrated interventions for alcohol and mental health problems 
Rubio et al. 
(2006) 
Pre-post 
open label 
trial  
N=28 
(10 female) 
Mean age 
36.5 years 
18-65 years 
Lamotrigine  
and 
individual 
relapse-
prevention 
programme   
Alcohol use 
 
Psychiatric 
symptoms 
 
 
SADS 
VASC 
TLFB  
CDT 
HAM-D 
YMRS 
BPRS 
ECG 
Outpatient 
Baseline, 2, 
4, 6, 8, 10, 
12 weeks 
Significant 
improvement was 
observed in psychiatric 
scores (p < 0.01). 
Craving and alcohol 
consumption also 
significantly decreased 
(p < 0.001). 
No control or 
comparison 
 
Other medications 
taken 
 
Psychosocial interventions for alcohol and mental health problems 
Agyapong et 
al. (2013) 
RCT 
EG n=24 
46% male  
mean age 
48 years 
 
CG n=24 
46% male  
mean age 
49 years 
Mobile phone 
text messages 
vs brief text 
message 
Alcohol use 
 
Depression 
CAD  
 
BDI-II  
Home 
Baseline, 6 
months 
Benefits of text 
message intervention 
were not sustained 
beyond the period of 3 
months. 
Small sample 
 
Attrition at follow 
up  
 
CBT for both 
groups as well 
 
Andrisano-
Ruggieri et al. 
(2016) 
Pre-post 
design  
n=7 
43% male 
Age range 
35-57 years  
Group 
counselling 
CBT sessions 
 
Alcohol use 
 
Psychiatric 
symptoms 
MALT 
 
PANSS  
Outpatient  
Baseline, 6 
months 
The PANSS and 
MALT scores indicated 
there was no 
significant reduction of 
the alcohol use or 
psychiatric symptoms 
after treatment.   
Limited data 
analysis 
 
Small sample 
 
No control group 
or comparison 
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Baker et al. 
(2002) 
RCT 
EG n=79 
75% male 
Mean age 
31.71 years 
 
CG n=81 
75% male 
Mean age 
30.05 years 
MI vs BI 
 
Alcohol and 
Drug use 
 
Psychiatric 
syndromes 
 
OTI 
 
BSI 
Inpatient  
Baseline, 3, 
6 and 12 
months 
Both groups improved 
over time on alcohol 
and psychiatric 
symptoms however 
this was not significant 
different at 12 months. 
Heterogeneous 
sample  
 
Attrition at follow 
up 
Brown et al. 
(2011) 
RCT 
n= 151 
67% male 
 mean age 
40.8 years 
CBT-D vs TAU 
Alcohol use 
 
Depression 
BDI 
MHRSD 
TLFB  
Outpatient 
Baseline, 6 
weeks, 3, 6, 
12 months 
Significant 
improvement for all 
patient on alcohol use 
and depression.  No 
difference between 
groups on abstinence; 
depression 
significantly lower for 
treatment group only 
at 6-week follow up 
(p=.05). Not significant 
for MHRSD. 
Baseline 
treatment  
Deady et al. 
(2016) 
RCT 
EG n=60 
40% male 
Mean age 
21.85 years 
 
CG n=44  
41% male 
Mean age 
21.59 years 
Online CBT/MI 
vs online 
control 
Alcohol use 
 
Depression 
PHQ-9 
 
TOT-AL 
Outpatient 
Baseline, 3 
& 6 months 
Improvement in 
depression symptoms 
(p<.001) and alcohol 
use outcomes (p<.001) 
however gains not 
maintained at follow-
up. 
Attrition at follow 
up 
 
Small sample size 
 
Error in 
randomisation 
Geisner et al. 
(2016) 
RCT 
N=311  
(EG n= 
76)37.6% 
male  
Mean age 
20.14 years 
Online CBT/MI 
vs TAU 
Alcohol use 
 
Depression 
AUDIT 
BDI-II  
DDQ 
RAPI  
PHQ-9 
University 
Baseline, 1 
month 
There were no 
significant differences 
across the study 
conditions for any of 
the outcome measures 
however alcohol 
intervention resulted in 
Non-patient 
sample 
 
Attrition at follow 
up  
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a reduction in alcohol 
related problems in 
those with a lower 
depressed mood 
compared to controls. 
James et al. 
(2004) 
RCT 
EG n=29 
71.9% male 
mean age 
28.50 years 
 
CG n=29 
71.0% 
males, 
mean age 
26.87 years 
Group-based 
CBT vs one 
session 
Alcohol and 
drug use 
 
Psychiatric 
symptoms 
POLYTOT 
SADS 
AUDIT  
GSI 
DAST 
CPZ 
BPRS  
Outpatient  
Baseline, 6 
weeks 
Significant reductions 
treatment group 
observed in 
psychopathology 
(p<.01), CPZ (p<.01), 
alcohol and illicit 
substance use 
(p<.001), severity of 
dependence and 
hospitalisation. 
Short follow up 
 
Attrition at follow 
up 
 
Small sample 
 
Study design 
Kay-Lambkin 
et al. (2008) 
RCT 
n=97 
46% male 
Mean age 
35.37 years  
 
Therapist led 
SHADE 
therapy vs 
Computer 
delivered 
SHADE 
therapy vs 
control 
 
 
Alcohol and 
drug use 
 
Depression 
BDI-II 
OTI 
SCID-RV  
Outpatient  
Baseline, 3, 
6, 12 
months 
Depression responded 
better to intensive 
SHADE intervention 
compared to BI alone. 
Therapist lead 
treatment 
demonstrated a strong 
short-term beneficial 
effect which was 
matched by computer-
based treatment at 12-
month follow-up. 
Problematic alcohol 
use responded well to 
BI alone and even 
better to the intensive 
MI/CBT intervention. 
Baseline 
treatment  
 
Small sample size 
 
 
Heterogeneous 
sample 
 
 
Morley et al. 
(2016) 
RCT 
n=37  
(46% male) 
mean age 
41 years 
CBT vs TAU 
Alcohol use 
 
Psychiatric 
symptoms 
TLFB, 
OCDS  
ADS 
ADIS-IV 
DASS-21 
Outpatient  
Baseline, 3, 
12, 16 and 
24 weeks 
Significantly higher 
abstinence for 
treatment group on 
abstinence and days 
to relapse (heavy 
drinking; p<.05) over 
usual care (BI) and 
days until relapse (any 
drinking; p<.01). No 
Short follow up 
 
Small sample 
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significant difference in 
depression between 
groups. 
Toneatto & 
Calderwood 
(2015) 
RCT 
n=123 
61% male  
mean age 
39.43 years 
CBT plus 
anxiety 
sessions vs 
CBT sessions  
Alcohol use 
 
Psychiatric 
symptoms 
TFLB 
SCL90  
BAI  
Outpatient  
Baseline, 6 
months 
(average 10 
months) 
Significant reduction of 
quantity and frequency 
of alcohol misuse 
(p<.001) and anxiety 
(p<.001). However, no 
advantage of extra 
anxiety sessions. 
Small sample 
 
Attrition at follow 
up 
 
Other medications 
taken 
 
Heterogeneous 
sample 
Pharmacological interventions for alcohol and mental health problems 
Bogenschutz 
et al. (2016) 
Pre-post 
open label 
trial  
n=41  
39% male 
Mean age 
41.66 years 
Disulfiram and 
Lorazepam 
(combined)   
 
 
Alcohol use 
 
Anxiety 
disorder  
TLFB, 
CIWA-Ar 
HAM-A 
HAM-D 
MINI  
Outpatient  
Baseline, 1, 
2, 4, 6, 8, 
10, 12, 16, 
28 weeks 
Combined treatment of 
alcohol use showed 
significant increases in 
percent abstinent days 
(p<.0005) during 
treatment and at 24-
week follow-up. Large 
reductions in anxiety, 
depression, and 
craving were observed 
during treatment, and 
improvement remained 
significant at 24 
weeks. 
Pilot study 
 
Small sample 
 
No control group 
or comparison 
 
Sample 
heterogeneity 
(medications; 
drug use and 
other comorbid 
syndromes) 
 
Missing data 
Brady et al. 
(2005) 
RCT: double 
blind 
placebo-
controlled 
trial 
EG n=49 3 
57% male 
Mean age 
6.7 years  
 
CG n=45 
51% male 
Sertraline vs 
Placebo 
Alcohol use  
 
PTSD 
CAPS 
SCID  
TLFB 
OCDS 
ASI 
HAM-D 
Outpatient 
Baseline, 
12 weeks 
Significant reduction in 
drinking or depression 
for both groups but not 
significantly different. 
Lower alcohol disorder 
(AD) and early onset 
PTSD had greater 
reduction in AD with 
Small sample 
 
Other comorbid 
diagnoses 
 
Baseline 
treatment  
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Mean age 
36.6 years  
active treatment 
(<.001). More severe 
AD and later onset of 
PTSD had significantly 
reductions in drinking 
(p<.05). 
Attrition at follow 
up 
Brown et al. 
(2009) 
RCT: double 
blind 
placebo-
controlled 
trial 
EG n=20 
50% male 
Mean age 
39.8 years 
 
CG n=23 
52.2% male 
Mean age 
43.2 years 
Naltrexone vs 
Placebo 
Alcohol use 
 
Bipolar 
disorder 
MINI 
HAM-D 
IDS-SR 
YMRS 
PACS 
PRD-111 
ASI  
GGT 
Outpatient 
Baseline, 
12 weeks 
No significant 
differences between 
groups. 
Small sample 
 
Attrition at follow 
up  
 
Baseline 
treatment 
Brown et al. 
(2014) 
RCT: double 
blind 
placebo-
controlled  
trial 
 
EG n=44 
61.4% male 
Mean age 
43.4 years  
 
CG n=44 
56.8% male 
Mean age 
39.7 years 
Quetiapine s 
Placebo 
Alcohol use 
 
Psychiatric 
symptoms 
 
 
HRSD 
IDS-SR, 
YMRS, 
CIWA-Ar, 
PACS, 
PRD-III, 
AIMS, 
SAS, 
BARS, 
TLFB, AST, 
ALT, GGT, 
UDS 
Outpatient 
Baseline, 
12 weeks 
No significant 
difference in craving 
and alcohol use. No 
difference in 
psychiatric symptoms 
expect IDS-SR in 
favour of treatment 
group (p=.07). 
Small sample 
 
Heterogeneity 
(medications) 
 
Low adherence 
Di Nicola et al. 
(2017) 
Pre-post 
Naturalistic 
study 
n=65 
64.6% male 
Mean age 
44.17 years 
Nalmefene  
Alcohol use 
 
Psychiatric 
symptoms 
 
 
HDD, TAC, 
CGI-S, 
VASc 
OCDS, 
BPRS, 
HAM-D 
YMRS  
Outpatient   
Baseline, 
24 weeks 
Nalmefene reduced 
drinking and craving in 
alcohol use disorder 
patients with and w/o 
comorbidity (p<.001). 
No control group 
or comparison 
 
Small sample 
 
Sample 
heterogeneity 
(medications; 
other comorbid 
syndromes) 
 
Study design 
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Gual et al. 
(2003) 
RCT: double 
blind 
placebo-
controlled 
trial 
n=83  
53% male 
mean age 
47 years 
Sertraline vs 
placebo 
Alcohol use 
 
Depression 
HRSD, 
MADRS, 
DD 
HDD 
Outpatient 
Baseline, 
24 weeks 
No significant 
differences between 
groups on alcohol or 
depression outcomes. 
Significant difference 
when groups were 
stratified into severe or 
moderate MADRS. 
Improvement (p=.038) 
and remission (p=.042) 
was reported for those 
with severe depression 
only. 
Small sample 
 
Low baseline 
scores 
 
Attrition at follow 
up  
Hernandez-
Avila et al. 
(2004) 
RCT: double 
blind 
placebo-
controlled 
trial 
EG n=21 
47.6% male 
Mean age 
43.1 years 
 
CG n=20 
50% male 
Mean age 
42.7 years  
Nefazodone vs 
Placebo 
Alcohol use 
 
Psychiatric 
symptoms 
TLFB, 
HAM-D, 
SAI, PSQI  
Outpatient 
Baseline, 
10 weeks 
Depression and 
anxiety reduced 
significantly over time 
(p=.01; p=.04). 
Treatment group had 
significantly greater 
reduction in HDD than 
placebos (p=.003). 
Small sample 
 
Attrition at follow 
up 
 
Low baseline 
scores 
Martinotti et al. 
(2008) 
Pre-post 
open label 
trial 
N=28  
71% male 
Mean age 
32.2 years 
Quetiapine 
(anti-
psychotic) 
Alcohol use 
 
Psychiatric 
symptoms  
EuropASI, 
OCDS, 
VAS, 
CIWA-Ar, 
BPRS, 
YMRS, 
HRDS, 
CGI, AST, 
ALT, GGT 
Outpatient  
Baseline, 
16 weeks 
Significant reduction 
alcohol use (p=.005), 
OCDS (p<.001) and 
craving (p=.018).  
Significant 
improvement in 
depressive symptoms 
(p<.001) and BPRS 
(p=.001). 
Small sample 
 
Heterogeneity 
sample 
(psychiatric 
diagnoses) 
 
Study design 
 
No control 
Petrakis et al. 
(2005) 
RCT with 
open label 
n=254 
97.2% male 
mean age 
47 years 
Disulfiram vs 
placebo OR 
Naltrexone 
alone OR 
Placebo OR 
Disulfiram and 
Naltrexone 
Alcohol use 
 
Psychiatric 
symptoms 
OCDS  
GGT 
HSCL 
TLFB 
CAPS 
Outpatient 
Baseline, 
12 weeks 
69.7% of all subjects 
achieved complete 
abstinence during the 
trial.  Active 
medication groups had 
significantly better 
drinking outcomes 
than those given 
placebo (p=.02), more 
Predominately 
male sample 
 
Attrition at follow 
up 
 
Study design 
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consecutive days of 
abstinence (p=.04) and 
a significant reduction 
of psychopathology for 
(<.02). 
Pettinati et al. 
(2010) 
RCT: double 
blind 
placebo-
controlled 
trial 
n=170; 
64.7% male 
mean age 
43.4 years 
Sertraline OR 
Naltrexone OR 
Sertraline and 
Naltrexone OR 
placebo 
 
Alcohol use 
 
Depression 
ASI, TLFB, 
HAM-D, 
SCID-D 
(subscale) 
Outpatient 
Baseline, 
14 weeks 
More patient receiving 
sertraline plus 
naltrexone 
combination achieved 
abstinence from 
alcohol (p=.001), had 
delayed relapse to 
heavy drinking 
(p=.003), reported 
fewer SAE (p<.02) and 
tended to not be 
depressed by the end 
of treatment. 
Heterogeneous 
sample (alcohol 
and drugs) 
 
Attrition at follow 
up 
 
Baseline 
treatment  
 
Placebo not 
described 
 
Short follow up 
 
Ralevski et al. 
(2011) 
RCT: double 
blind 
placebo-
controlled 
trial 
n=23 
83% male 
mean age 
50.73 years 
Acamprosate 
vs Placebo 
Alcohol use 
 
Psychiatric 
symptoms 
TLFB 
OCDS 
PANSS 
Home 
Baseline, 1, 
2, 3, 4, 5, 6, 
7, 8, 9, 10, 
11, 12 
weeks 
Acamprosate was not 
more effective than 
placebo as all 
participants reduced 
drinking (non 
significant. Treatment 
group had improved 
psychiatric symptoms 
(non significant). 
Small sample 
 
Attrition at follow 
up 
 
Placebo not 
described 
Salloum et al. 
(2005) 
RCT: double 
blind 
placebo-
controlled 
trial 
EG n=29 
72% male 
Mean age 
37 years 
 
CG n=30 
77% male 
mean age 
38  years 
Lithium and 
Valproate vs 
Lithium and 
placebo   
Alcohol use 
 
Bipolar 
disorder 
 
BRMS, 
HRSD, 
TLFB 
Outpatient 
Baseline, 
12 weeks 
Significantly reduced 
alcohol consumption 
(p=.02) and longer 
period to relapse 
(p=.048) in both 
groups. 
Small sample  
 
Attrition at follow 
up 
 
Heterogeneity  
(comorbid mental 
health problems) 
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 (see appendix C for list of screening tools used) 
Tolliver et al. 
(2012) 
RCT: double 
blind 
placebo-
controlled 
trial 
EG n=14  
71.4% male 
mean age 
40.8 years  
 
CG n= 
1656.3% 
male Mean 
age  43.7 
years 
Acamprosate 
vs Placebo 
 
Alcohol use 
 
Psychiatric 
symptoms  
MINI 
GGT 
CDT  
ALT/ AST 
TLFB 
OCDS 
MADRS 
YMRS 
CGI-S/I  
GGT 
Outpatient  
Baseline, 1, 
2, 3, 4, 5, 6, 
7, 8 weeks 
Acamprosate was not 
significantly different at 
endpoint compared to 
placebo for alcohol 
consumption or 
psychiatric symptoms. 
 
Small sample 
 
Attrition at follow 
up 
 
Placebo not 
described 
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Findings – Psychosocial Studies 
 
Ten studies were identified using a psychosocial intervention. Three studies conducted 
CBT based interventions. Toneatto and Calderwood (2015) compared CBT sessions with 
CBT and additional anxiety sessions. This study reported significant reductions of 
quantity and frequency of alcohol use (p<.001) and anxiety (p<.001) in both groups. 
However, extra anxiety sessions were not deemed advantageous.  Morley and 
colleagues also reported a beneficial effect of specialised CBT including days to relapse 
decrease (p<.05) compared to brief individualised motivation enhancement therapy 
(Morley et al., 2016).  However, there was no significant differences for depression and 
anxiety scores.  Brown et al. (2011) conducted an RCT whereby patients were assigned 
to receive eight individual sessions of CBT-D which included a coping with depression 
course modified for use with alcohol patients as well as focusing on daily mood 
monitoring, pleasant activities, constructive thinking, and social skills and assertiveness.  
 
After six weeks, no differences were found between CBT-D and an individualised 
relaxation training programme relating to abstinence, however, on one measure of 
depression, scores were significantly lower for treatment group at 6-week follow up 
(p=.05).  However, a limitation of this study is that all patients received the standard 
group therapy which is CBT based which may have influenced outcomes. One study 
used motivational interviewing (MI) with inpatients  and demonstrated short-term benefits 
in reducing alcohol consumption and depressive/anxiety symptoms compared to brief 
information relating to reducing substance abuse. At the three-month follow up juncture 
there was a significant reduction in alcohol use (p≤.01) and depression indicators 
(p≤.001) although these results were not replicated at 6 and 12-month follow up time 
frames (Baker et al., 2002).    
Two studies used group-based interventions.  Andrisano-Ruggieri et al. (2016) conducted 
group counselling for 6 months; validated tools indicated there was no reduction of the 
psychiatric symptoms after treatment at follow up (6 months after study finished). 
Furthermore, the study findings were undermined by poor reporting of findings and a 
weak design. James et al. (2004) conducted manualised group-based interventions. This 
included the following topics for six weeks (1) psycho-education on drug use and mental 
health; (2) reasons for use; (3) reasons to change; (4) harm reduction strategies; (5) 
coping with high-risk situations and assertiveness training; and (6) planning for the future 
which encompassed peer support, motivational enhancement strategies, harm 
minimisation and relapse prevention paradigms. At follow up (three months), significant 
reductions in favour of treatment group was observed in psychopathology (p<.01), 
alcohol and illicit substance use (p<.001) and severity of dependence and hospitalisation. 
However, methodological issues include heterogeneity in the sample, blinding and 
randomisation concerns. 
 
Four studies used technology-based CBT interventions (Agyapong et al., 2013; Deady et 
al., 2016; Geisner et al., 2016; Kay-Lambkin et al., 2008).  Agyapong et al., (2003) 
implemented a three-month recovery support intervention in the form of text messaging. 
Participants received two daily text messages promoting good mental wellbeing, dealing 
with stress, promoting abstinence from alcohol, dealing with cravings, promoting 
adherence with medication and providing general support for three months, followed up 
at six months. At three months, positive effects for abstinence and depression were 
reported. However, compared to controls, who received fortnightly ‘thank you’ text 
messages, the effects were not sustained beyond the three month period (Agyapong et 
al., 2013).  Limitations relate to a small sample despite low attrition at follow up.  Deady 
et al., (2016) conducted an RCT comparing two online computer interventions: The Deal 
Project and Healthwatch. The Deal Project involved an online CBT and MI intervention 
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implemented via a website that required the completion of ten modules (4x1 hour) over 4 
weeks. Healthwatch involved 12 online attention control modules, whereby patients read 
information about various health concerns and completed surveys (for example about 
physical and mental health activity) which acted as a control. Results for the Deal 
intervention indicated that there were significant reductions in severity of depression 
symptoms (p≤.001) and reduction in number of drinks per week (p≤.001) compared to 
control group.  However, authors refer to limitations including randomisation concerns.  
 
Geisner et al., (2016) also conducted an online CBT intervention.  The intervention 
involved online computer sessions of personalised feedback and psycho-education 
compared to treatment as usual (TAU) which involved a treatment resource, providing 
information on depression and substance use but did not view any personalised 
feedback or intervention materials.  Despite no significant differences across the study 
conditions for any of the outcome measures, participants in the intervention group 
showed a reduction in alcohol-related problems at follow up compared to the control 
group. It is important to note that unlike other studies in this review, this sample included 
college students and were not from a patient population.  Kay-Lambkin et al., (2008) also 
conducted an RCT using integrated CBT and MI provided by trained therapists compared 
to a computer delivered intensive therapy programme entitled ‘SHADE’. The therapist-led 
intervention consisted of ten individual sessions of therapy, one week apart, delivered by 
a psychologist. These sessions incorporated cognitive behavioural therapy (CBT) and 
motivational interviewing (MI) components. The computer-led intervention was identical 
to the therapist-led intervention but also included interactive components such as video 
demonstrations and in-session exercises.  In addition, a third group receiving no 
treatment acted as control.  The computer-based treatment had the largest treatment 
effect followed by combined CBT and MI for depression scores and a reduction in 
problematic alcohol use. However, this was an underpowered study due to the small 
sample size across three groups (n=97). In addition, a brief CBT session was provided to 
all participants at baseline before randomisation which may have influenced results.  
 
Findings - Pharmacological Studies  
 
Thirteen studies were identified using a pharmacological intervention for comorbid mental 
health conditions and problematic alcohol use. Although Naltrexone was the most 
commonly administered drug it was assessed in various ways.   
 
Naltrexone (drug to combat alcohol craving) was compared against placebo, combined 
with or compared to other drugs.  Brown et al. (2011) conducted a double blind RCT 
comparing Naltrexone and placebo however there were no significant differences 
between groups relating to alcohol use and psychiatric symptoms after 12 weeks.  
Nalmefene, a derivative of Naltrexone, was administered to patients with alcohol and 
drug problems with and without a psychiatric comorbidity. Nalmefene was reported to 
have significantly reduced drinking and craving in alcohol use disorder patients (Di Nicola 
et al., 2017; p<.001) but there was no difference between those with and without 
comorbidity. This was a pre-post naturalistic design study and no control or comparison 
was provided. 
  
Petrakis et al. (2005) conducted a 12-week open label RCT comparing Naltrexone, 
Disulfiram (produces an acute sensitivity to drinking alcohol) alongside combined 
Naltrexone and Disulfiram and placebo arms. Active medication groups had significantly 
more consecutive days of abstinence (p=.04), however, 69.7% of all subjects achieved 
complete abstinence during the trial.  Active medication groups also had significantly less 
cravings (p=.02) and obsessive alcohol thoughts (p=.02) compared to those treated with 
placebo. There was also a significant reduction in paranoid ideation (p=.02) for those 
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receiving medication. However, caution should be taken in generalisation given this was 
a mixed study design (blinding and open label), an overrepresentation of males (97%) 
and high attrition at follow up.  
 
A double blind RCT by Pettinati et al. (2011) indicated that Naltrexone combined with 
Sertraline (anti-depressant) was more effective than used as separate interventions. 
Patients reported more abstinence days for the combined drugs (p<.001), did not drink as 
heavily (p<.001) and reported a longer time before relapse (p=.003) and were more likely 
to not be depressed by the end of treatment, however, this was not statistically 
significant. Other issues include attrition at follow up, short follow up and inclusion of 
patients with multiple substance abuse problems.  Interestingly, Gual et al. (2003) 
reported no significant differences between groups on abstinence or depression who 
were given either Sertraline or placebo.  However, 72% remained abstinent during the 
24-week trial.  In addition, those with severe depression were more likely to improve 
(p=.038) and experience remission of comorbid depression (p=.042)Similarly, Brady et al. 
(2005) in a double blind RCT placebo trial administrated Sertraline and placebo, finding 
no significant differences between groups, however, those with early onset of PTSD had 
a greater reduction (p<.001) in alcohol use with active treatment. Hernandez-Avila et 
al.(2004) also used the anti-depressant Nefazodone which significantly reduced heavy 
drinking days (p=.003), depression (p=.01) and anxiety (p=.04) compared to a placebo. 
However, both studies had small samples and had high attrition at follow up.   
Mixed findings are reported by two studies using Quetiapine (anti-psychotic) compared to 
placebo (Martinotti et al., 2008; Brown et al., 2014). Despite the small sample and pre 
post-test design, Martinotti et al. (2008) reported a significant reduction in alcohol use 
(p=.005) and cravings after 16 weeks, as well as a significant improvement in 
psychopathology (p<.001) within the treatment group. Brown et al. (2014) conducted an 
intention to treat, double blind RCT and found no significant difference in alcohol use or 
cravings after 12 weeks. Whilst the authors did find an improvement in psychiatric 
symptoms this was only recorded via one outcome measure (IDS-SR; p=.007) in favour 
of the treatment group.  Salloum et al. (2005) conducted a double blind RCT using 
Lithium (anti- psychotic) and Valproate (anti-convulsant) compared to lithium and placebo 
to reduce alcohol use with comorbid bipolar disorder. Both groups reported a significant 
reduction in alcohol use and a longer time to relapsing after 12 weeks. However, this 
study described high attrition at follow up.  
 
Bogenschutz et al. (2016) conducted an open label pre-post design study combining  
Disulfiram and Lorazepam (drug used to treat anxiety) to treat individuals with alcohol 
dependence and an anxiety disorder with or without co-occurring major depression. 
Results highlighted that this was successful in reducing alcohol use and anxiety 
(Bogenschutz et al., 2016).  There were significant increases in percentage of abstinent 
days (p<.0005) during treatment and at 24-week follow-up.  Significant reductions were 
also found in anxiety, depression, and craving during treatment and improvement 
remained significant at 24 weeks (p<.05). However, no control group was used, and the 
sample size was small (n=41). Acamprosate (used to reduce urges to drink alcohol) was 
used in two double blind RCT studies and was found to have no effect on alcohol use 
(Ralevski et al., 2011; Tolliver et al., 2012) when compared to placebo.  In addition, no 
significant differences were reported for mood outcomes and despite a reduction in 
schizophrenic symptoms this was not significantly different.  Methodological issues 
include a small sample size and attrition at follow up.  
 
Findings – Integrated Studies 
 
One study implemented an integrated treatment (Rubio et al., 2006). A 12-week open 
label RCT used Lamotrigine (a drug treatment for depression in adults with bipolar 
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disorder) in combination with a weekly relapse-prevention programme. The programme 
involved patients attending weekly interviews as regards their consumption, craving and 
to analyse psychopathological symptoms.  The study reported significant improvement in 
depression, mood and psychiatric symptoms (p<.01). In addition, craving and alcohol 
consumption significantly reduced during treatment (p<.001; Rubio et al., 2006). Despite 
this, the psychosocial component was not clearly described preventing replication, a 
range of prescribed drugs were used by patients and no control group included. 
 
Research Aim Two - Review of Policy and Treatment Models 
 
The second research aim in the review focused on the general policy framework for dual 
diagnosis, assessment models, care plans and guidelines for practice within the UK. In 
addition, there was a specific focus on models of service delivery within UK and 
international contexts.  
 
Policy Framework (UK) 
 
In England, Government policies for alcohol and mental health have developed in a 
separatist fashion over the past few decades. A series of strategies including the National 
Service Framework for Mental Health (NHS, 1999) and No Health without Mental Health 
(HM Government, 2011) made very little reference to alcohol or drug comorbid 
conditions. However, the Five Year Forward view for Mental Health (Mental Health 
Taskforce, 2016) did make a brief recommendation on funding which should be used 
locally for those regions that could demonstrate integration of assessment and care 
planning alongside treatment for those individuals with comorbidity.  Similarly, there is a 
lack of focus on comorbidity in The Government’s Alcohol Strategy (HM Government, 
2012). The 2012 document included only two paragraphs to note the association 
between alcohol and mental health but did not provide any recommendations as to how 
issues could be addressed in policy or practice.  
 
However, in retrospect an older document published by Department of Health England 
(2002) published a definitive Dual Diagnosis Good Practice Guide which highlighted that 
an integrated model of service provision should be implemented for dually diagnosed 
individuals rather than the serial or parallel models of practice. It highlighted that dual 
diagnosis services should be led by community health teams with a corollary role for 
substance misuse services to work in partnership to best fulfil the needs of the service 
users. This was also reflected in the Bamford report (2005) in Northern Ireland which also 
purported the integrated service model as the most beneficial for the delivery of series for 
this specific grouping. 
 
The current Welsh Government policy ‘Together for Mental Health: A Strategy for Mental 
Health and Wellbeing in Wales’ (2012) recognises the problems that are experienced by 
individuals with co-occurring mental health problems and alcohol or drug abuse and also 
advocates an integrated service model for addressing the problems experienced by this 
service user group. Similarly, the Drugs and Alcohol Strategy for Wales ‘Working 
Together to Reduce Harm’ (2008) also stipulates that services must work together to 
prevent individuals who have a dual diagnosis from ‘falling between the gaps’ in service 
provision. The government in Wales also produced a comprehensive policy framework 
which specifically addresses the needs of people with comorbid disorders. The document 
highlights the recovery approach for mental health and substance misuse services, whist 
focusing on co production, addressing the specific needs of the individual, improving 
accessibility to services and ethos of person-centred care (Government of Wales, 2015). 
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In Scotland, the current Mental Health Strategy 2017-2027 (Scottish Government, 2017) 
underlines that relevant alcohol, drugs, mental health services and social services should 
work in partnership to ensure an holistic approach to addressing the needs of their 
service users who have a dual diagnosis. The document proffers two action points in 
relation to working with clients who have comorbid substance use and mental health 
disorders. 
 
1 To employ evidence-based assessment and referral pathways for people with 
comorbid substance use and mental health diagnoses.   
2 Introduce pilot programmes which are based on ‘improved arrangements’ for people 
with dual diagnosis (although it is not entirely clear whether this is evidenced-based or 
not), (Scottish Government, 2017).  
 
Furthermore, Scotland’s most recent joint strategy on alcohol and drug treatment 
underlines that the Government will consider structured methods and joint working for 
people who present with alcohol/drug and mental health comorbidities (Scottish 
Government, 2018). Scotland also has separate alcohol policy documents ‘Changing 
Scotland’s Relationship with Alcohol: A Framework for Action’ (Scottish Government, 
2009) and the recent ‘Alcohol Framework 2018: Preventing Harm next steps on changing 
our relationship with alcohol’ (Scottish Government, 2018). However, these framework 
documents focus more on reducing consumption, (including Minimum Unit Pricing) 
encouraging positive choices, education, awareness changing, and behaviour change 
with little reference to co-occurring disorders. 
 
In Northern Ireland, the most notable regional policy review on dual diagnosis was 
published in 2005. The Bamford Report provided discussion on models of assessment 
and models of treatment for comorbid disorders. Since the publication of the report, there 
has been little reference made to comorbid substance use disorders and substance use 
in drug and alcohol and mental health policies in Northern Ireland. As regards drug and 
alcohol policy frameworks, the New Strategic Direction in Drugs and Alcohol 2011-2016 
made brief reference to mental health as a specialist area within the framework with a 
recognition that there was need for further coordination between mental health, drug and 
alcohol use and suicide (DOH, 2016). 
 
Assessment Models (UK) 
 
The overview of the information below summarises general guidelines for comorbid 
mental health disorders with substance use problems (including alcohol) and indicates 
where there is specific policy reference to alcohol only comorbid diagnoses.  
 
The DOH Good Practice Guide (2002) stipulated that the assessment process in relation 
to comorbid mental health and substance use disorders should be comprised of detection 
and screening (via self-report, lab tests and comprehensive data gathering), specialised 
assessment (through comprehensive, longitudinal use of validated assessment 
instruments and under continuous review) and risk assessment (including gauge of 
severity of substance use, consideration of adulterants, risk or overdose and/or suicide).  
 
Assessment should also be tailored to the needs of specific vulnerable groups including 
women, young people, people who are homeless, those involved in the criminal justice 
system and people from ethnic minorities (DOH, 2002). Components of assessment are 
highlighted in the guide and whilst the document is outdated the main foundations of 
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assessment remain relevant to current practice. The information presented in table three 
also draws upon some of the guiding principles outlined by Rethink (2017). 
 
Table 3: Assessment Components  
 
Assessment Components 
Identification and response to any emergency or acute problem 
Assessment of patterns of substance misuse and degree of 
dependence/withdrawal problems  
Assessment of physical, social and mental health problems  
Evaluate the relationship between substance misuse and mental 
health problems 
Consider the clients concerns as central to the assessment process 
which may seem intimidating to some individuals and may lead to 
disengagement 
Consider any likely interaction between medication and other 
substances   
Consider of a range of needs including medical and social care, 
food shelter, access to primary care and child care 
Timelines can be useful to ascertain priorities for treatment and 
include assessment of treatment history  
Determine an individual’s expectation of treatment and their degree 
of motivation for change  
Make an assessment of carer involvement and need  
Undertake an assessment of knowledge of harm minimisation in 
relation to substance misuse   
Utilize a strengths-based approach to assessment recognising the 
achievements of the individual 
Consider the need for pharmacotherapy for substance misuse  
Notification to the National Drug Treatment Monitoring System 
 
(Source: DOH, 2002, p.18; Rethink, 2017 p.25) 
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Assessment in specialist alcohol services is guided by the NICE (2011) document on 
Diagnosis and Assessment of Harmful Drinking and Alcohol Dependence. It 
recommends that for those who have a significant comorbidity the assessment goals 
may initially be based on a harm reduction approach but ultimately abstinence from 
alcohol would be the preferred objective (NICE, 2011). 
 
Guidance on severe mental illness and co-occurring substance use problems published 
by NICE (2016) indicated that assessment processes should be underpinned by a 
person-centred, empathic and non-judgemental approach based on respect and trust. 
The importance of the person-centred nature of the assessment was also reiterated in 
the NICE guidelines document on coexisting severe mental illness and substance 
misuse and service user experiences in mental health (NICE 2016).  In addition, a report 
by Hawkins et al. (2013) indicated that service users felt that a good dual diagnosis 
assessment involves asking a range of relevant questions, actively listening to the 
responses, avoiding pre-conceived notions based on stereotypes or diagnoses, 
matching the needs of individuals to a range of treatment options, avoiding repetition of 
information gathering and utilising a person centred approach (Hawkings et al., 2013).   
 
A number of regional NHS Trust Dual Diagnosis strategies also make reference to the 
principles of a person-centred approach (North East London, 2008; Somerset 
Partnership, 2017). There is also direction regarding where service users should be 
accommodated when presenting for assessment and it is recommended that the person 
should remain with the organisation of first contact, either the mental health team or the 
substance use team, until a comprehensive assessment has been undertaken. Where 
possible there should be a joint assessment across both agencies (North East London, 
2008). However, regional documentation also specifies that the management of more 
severe mental health illnesses should remain with the mental health team from the point 
of assessment with management of disorders such as anxiety and moderate depressive 
disorders staying with the substance use specialist teams (Bamford, 2005; North East 
London Trust, 2008). 
 
It is also recognised that it may be difficult to assess whether the substance use disorder 
or the mental health disorder is the main problem at the time of the initial assessment. 
For example, use of new psychoactive substances or stimulants may induce a temporary 
psychotic episode similar to that seen in schizophrenia presentations but it is usually the 
case that symptoms dissipate following a period of abstinence, unlike a psychotic illness 
where the symptoms will be prolonged and more variable. Likewise, symptoms of 
anxiety and depressive disorders indicated in some individuals with an alcohol use 
disorder “may resolve following detoxification and standard treatment for alcohol 
dependence” (Bamford, 2005 p.6).   
 
Shunting of service users at the assessment stage is often apparent with a lack of clarity 
about which organisation is responsible for the management of care. Similarly, barriers 
as regards access to mental health agencies are reported when mental health teams 
exclude people whose problems are primarily with alcohol or drug use (Rethink, 2017). 
 
Assessment of risk is core to a process which is simply not confined to the initial phases 
of engagement but should be revisited in conjunction with the client on a regular basis. 
Risk assessment is also significant in the protection of the individual from harm to self or 
others or to the wider community, although it is likely that individuals with a dual 
diagnosis are at risk of harming themselves either through self-harm or suicide 
(University of Manchester, 2018). Practitioners should not avoid asking about risk 
behaviours as some fear that highlighting risk behaviours may likely encourage the client 
to engage in such behaviours rather than protect them. However, it is only through full 
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and honest engagement with the client that their concerns may be voiced to enable an 
adequate support system which protects them and others whilst working in partnership 
to provide them with choice and autonomy in respect of most aspects of their care 
(Rethink, 2017). 
 
Care Planning (UK) 
 
A successful model of care planning in working with people who have a dual diagnosis of 
alcohol and severe mental illnesses (SMIs) or mood disorders should mirror the 
preceding assessment in terms of overarching values including respect, dignity and 
empowerment of the individual in all parts of the care planning process. It should always 
be based on a co-production approach and should specify the goals that are achievable, 
highlight which agency should be involved in what aspect of the individual’s treatment 
plan, specify how and why information should be shared between agencies/partners, 
consider cultural ethnic specific issues and include a structured review date (Rethink, 
2017).  
 
In addition, NICE guidelines for Severe Mental Illness and Substance Use (2016) 
highlight that the care plan must also involve family carers, if the request is made by the 
individual, whilst ensuring that the care plan considers previous experiences and coping 
strategies and whether these identified strengths would enable them to recover more 
readily. It is also advised that goals should be agreed openly and in partnership with the 
individual and a concomitant partnership approach should also be operationalised at a 
structural level to include established and productive collaborative agency working. This 
will ultimately benefit the service user and address the specific needs of each individual 
in a holistic fashion to include accommodation, finances, and relationships. Crucially, 
service users should not be responsible for navigating between statutory and third sector 
services as regards mental health and substance use (NICE, 2016; Welsh Government, 
2015). 
 
Treatment Models (UK and International Models) 
 
The UK and international literature which considers treatment models for dual diagnosed 
individuals is consistent in highlighting three primary service delivery approaches which 
are applicable to hazardous or dependent alcohol use and/or drug use disorders with co-
occurring mental health disorders. First, the serial treatment model usually describes a 
care pathway whereby the individual’s mental health disorder and substance use 
disorder are treated by separate services at different junctures, for example people may 
be treated for substance use disorders prior to the mental health team treating their 
anxiety, paranoid delusions or depression (Abou-Saleh, 2004).   
 
Second, the parallel model involves treatment for comorbid disorders simultaneously but 
via separate treatment providers in different settings (EMCDDA, 2015). Third, a model of 
integrated treatment health is one whereby professionals working in one clinical setting 
provide comprehensive treatment for both disorders simultaneously with interventions 
that address both disorders (EMCDDA, 2015). Research data from international sources 
demonstrate that individuals with co-occurring mental illness and AuDs who receive 
treatment for both disorders simultaneously have better clinical outcomes (SAMHSA, 
2005; IOM, 2005; Mangrum et al., 2005; Muser et al., 2003; McCoy et al., 2003). Despite 
the evidence, many care service programmes tend to identify and treat only one of the 
two co-occurring disorders which often creates fragmented care and results in negative 
care outcomes and also increased risk of relapse (Drake, 2007).   
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Within mental health settings, the co-occurrence of alcohol misuse is highly relevant as it 
can destabilise patients and contribute to increased rates of relapse, readmission to 
hospital, physical health problems, suicidality, violence and social instability (Drake, 
2007).  However, mental health workers often do not feel confident to manage the 
alcohol use disorder, and so the patient’s care tends to be passed between substance 
use and mental health services. Clinical Guidance for alcohol use disorders (NICE, 
2011) stipulates that for alcohol misuse and comorbid depression or anxiety disorders 
the clinician should treat the alcohol misuse first as this may precipitate reduction of 
anxiety and depression symptoms. In addition, if the symptoms do not reduce over a 30-
34 week period the 2011 guidance highlights that the practitioner should refer to the 
appropriate NICE guidance for either disorder (See NICE, 20091; NICE, 20112). 
Furthermore, for those individuals who have an alcohol problem and a co-current serious 
mental illness (SMI) they should undergo comprehensive assessment, risk and 
assessment and treatment by a psychiatrist. In addition, people who have an SMI and 
alcohol problem should only be referred to psychological treatment if they have 
abstained from or have significantly reduced their alcohol intake (NICE, 2011a). 
 
In the United States integrated approaches to treatment that incorporate coordinated, 
systematic treatment of both co-occurring conditions within one programme are 
recommended as best practice for comorbid treatment (SAMHSA, 2005; IOM, 2005; 
Drake et al., 2001). The Affordable Care Act, passed in 2010 and fully implemented in 
2014, calls for increased integration and coordination of behavioural health services, as 
clients diagnosed with both SUD and mental illness are overrepresented in treatment 
samples (Croft & Parish, 2013). However, the need for advancement is evident as when 
assessing dual diagnosis capability in 256 mental health and substance use disorder 
treatment programmes across multiple state systems in the United States McGovern et 
al., (2014) found that only approximately 18% of addiction treatment and 9% of mental 
health programmes met criteria for dual diagnosis capable services.  Despite the 
development of training materials, such as SAMHSA’s (2013) Substance Abuse 
Treatment for Persons with Co-occurring Disorders, only a small minority of mental 
health and addiction treatment programmes offer integrated mental health care services 
(McGovern et al., 2014). It is currently recognised that persons with co-occurring 
disorders often have complex clinical needs that require integrated treatment in “primary 
care, human services, housing, criminal justice, education and related fields” 
(SAMHSA/COCE, 2005, p.3). However, currently there are multiple barriers to treatment 
in the United States that result in a lack of collaboration and integration between care 
delivery systems for mental illness and SUDs which results in high attrition rates and low 
compliance (Krawczyk et al., 2017). In a national sample assessing the association of 
psychiatric comorbidity with treatment completion among clients admitted to substance 
use treatment programs in the United States it was evident that clients with psychiatric 
comorbidity have lower SUD treatment retention (Krawczyk et al., 2017). And 
furthermore, comorbidity was most strongly associated with 
In Europe, expertise centres and consortiums have been established in a number of 
countries to enable organisations to more effectively implement integrated treatment. 
However, there are many differences in approaches, not only between European 
countries but also between different regions of the same country (van Wamel, et al., 
2015). Some countries, such as Finland, Italy, the Netherlands, Norway and Spain, have 
special facilities, including acute inpatient dual diagnosis units, dual diagnosis residential 
communities, and dual diagnosis programmes in both mental health and drug user 
                                            
1 NICE (2009) Depression the treatment and management of Depression in Adults, NICE clinical guideline 90.  
 
2 NICE (2011) Generalised panic disorder and panic disorder (with or without agoraphobia) in adults: management in 
primary, secondary and community care NICE clinical guideline 113. 
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outpatient centres which indicates attempts to move towards a more integrated model of 
treatment. EMCDDA, (2015) sourced specific data as regards treatment services for 
comorbid SUDs and mental illness in Europe and  have suggested that despite vast 
heterogeneity in treatment approaches a general approach can be extrapolated 
(EMCDDA, 2015). Addiction treatment services are provided both by specialised centres 
and as part of general healthcare services (e.g. psychosocial services and psychiatric 
hospitals). They provide a range of service  delivery options which can be applied to help 
address a client’s treatment and social needs. Treatment centres provide counselling, 
outreach work, psychotherapy, aftercare and reintegration programmes. Inpatient 
psychosocial interventions are provided in both specific and generic facilities (i.e. drug 
use centres and mental health centres), offering short- and long-term treatment, often 
combined with inpatient detoxification (EMCDDA, 2015). However, Ness et al. (2014) 
suggests that these differentiations in treatment facilities may be a barrier to the 
provision of appropriate treatment services for clients with comorbid disorders. 
Furthermore, other difficulties are related to the fact that treatment services may lack 
sufficient combined expertise to treat both types of disorders (Sacks et al., 2013).  
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Conclusions   
 
The term dual diagnosis is misleading as it implies the existence of only two disorders. 
Definitions of co-existing alcohol and mental health disorders can vary according to 
professional context and there may be some exclusion of the most prevalent mood 
disorders such as anxiety or depression. Subsequently, this may have an impact on the 
level of service provision afforded to the service user.  
 
The rate of alcohol-related harms and morbidity have increased in most regions of the 
UK nations over the last few years. Moreover, there are multi-faceted and complex 
associations between AuDs and the various psychiatric disorders and these relationships 
are nuanced in terms of direction and symptomology.  However, it is clear that there is a 
strong link between mental health disorders including depression, anxiety, bipolar 
disorder, personality disorder and schizophrenia. The evidence highlights that there is a 
strong association between AuDs and depression where increased alcohol intake may 
precipitate depression or exacerbate already existing symptoms. Furthermore, it is 
evident that there is a more reciprocal relationship between AuDs and anxiety, where 
withdrawal from the substance may intensify anxiety or individuals may attempt to 
ameliorate symptoms of anxiety via increased alcohol usage. As regards schizophrenia 
or schizoid affective disorders, alcohol has been reported as having sedative effects on 
symptoms of the disorders. Also, evidence suggests that there is a higher rate of suicide 
in people who have been diagnosed with AuDs and bipolar disorder. 
 
Across the UK, the policy framework for substance use disorders and mental health 
comorbidity is inconsistent and even more so in relation to alcohol-specific co-occurring 
disorders. In England the last comprehensive guide to policy and practice was published 
by the Department of Health in 2002, whilst in Northern Ireland there has been a gap in 
specific policy guidance for comorbid substance use and mental health disorders since 
2005. Conversely, in Wales the government produced a recent comprehensive policy 
framework which addressed the specific needs of people with comorbid disorders in 
2015.  Likewise, whilst Scotland may not have a recent specific policy framework 
document related to comorbidities, it does make a substantial reference to comorbid 
disorders in a number of mental health and alcohol policy frameworks (Scottish 
Government 2017; 2018).   
 
According to the evidence, all levels of assessment and care planning in working with 
comorbid disorders must be tailored to the complex individual needs of the service user 
(and carers where appropriate), be developed in full partnership with the service user 
(where possible) and founded on a non-judgemental, empathic and person-centred 
approach. Risk assessment is also an integral part of the care pathway and practitioners 
should provide an open and honest environment through which service users are 
enabled to voice their concerns and in doing so ensure the best possible support 
systems for the service users and their families.  The concept of ‘shunting’ service users 
between mental health and substance disorder services is often apparent with a lack of 
clarity about case management responsibility. Furthermore, NICE (2016) guidance 
recommends that initial goals for alcohol and mental health comorbidities may be agreed 
on the basis of a harm reduction approach but that the ultimate goal for this specific 
service user grouping should be abstinence. 
 
Three models of service delivery were identified from the literature:  
 
Serial - service users are treated separately by mental health or substance use 
disorder services at different times and locations; 
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Parallel - service users are treated simultaneously by separate treatment 
providers; 
 
Integrated- service users are treated concurrently by both mental health and 
substance use service providers in one setting. 
 
Whilst the integrated service model demonstrates more efficacious treatment outcomes 
(Mangrum et al., 2005; Muser et al., 2003; McCoy et al., 2003), it is not entirely clear how 
many treatment providers in the UK currently provide an integrated service for 
concomitant AuDs and mental health disorders.  However, there is the suggestion that 
the majority of treatment models in the UK and the United States tend to work within the 
parameters of the serial and parallel models.  In Europe there is substantial 
heterogeneity in the range of treatment models offered for co-existing disorders, although 
it is noted that the wide range of options may also act as barrier to treatment provision as 
some providers may lack the skills and expertise to address the needs incurred by both 
AuDs and mental health disorders. 
 
Result from a rapid structured review of interventions for alcohol use problems/disorders 
and comorbid mental health conditions showed mixed results for both pharmacological 
and psychosocial intervention studies.  Naltrexone (drug to combat alcohol craving), was 
the most commonly administered pharmacological intervention, however, mixed findings 
were reported when used in placebo-controlled trials (Brown et al., 2011; Di Nicola et al., 
2017). 
 
When combined with other drugs, Naltrexone demonstrated more positive outcomes for 
patients, than when used alone. Naltrexone combined with Disulfiram (produces an acute 
sensitivity to drinking alcohol) was successful at treating alcohol use and psychiatric 
symptoms compared to placebo (Petrakis et al., 2005). The use of Sertraline (anti-
depressant) with Naltrexone was also successful at reducing alcohol use and depression 
(Pettinati et al., 2011). Another combination of drug treatments using Disulfiram and 
lorazepam (drug used to treat anxiety) also demonstrated promising outcomes with 
reductions in alcohol use and psychiatric symptoms. Similar to Naltrexone, when 
Sertraline was used alone it was less successful at treating comorbid conditions (Gual et 
al., 2003).   
 
Quetiapine (anti–psychotic) also demonstrated mixed findings; Brown et al. (2014) found 
no reduction in alcohol cravings and an improvement in only one outcome measure for 
psychiatric symptoms whilst Marttinetti et al. (2008) reported reduction in both alcohol 
cravings and psychiatric symptom indicators. Another study combined an anti-psychotic 
with an anti-convulsant and reported a significant reduction in alcohol use and bipolar 
disorder. However, this was reported both within the treatment and placebo group 
(Salloum et al., 2005).  Single application of anti-anxiety medication such as 
Acamprosate was reported to be the least effective in the treatment of comorbid 
conditions (Tolliver et al., 2012; Ralevski et al., 2011). Whilst the majority of studies were 
RCTs, a few demonstrated significant methodological issues including lack of appropriate 
control groups, small sample sizes and high attrition rates.  
 
CBT was reported as an effective intervention in treating at least one aspect of comorbid 
problematic alcohol use and psychiatric conditions. Toneatto and Calderwood (2015) 
reported significant positive outcomes for reductions in both alcohol use and anxiety 
symptoms, Morely et al. (2016) highlighted a significant increase in days to relapse but 
no significant differences for depression and anxiety scores and  Brown et al. (2011) 
reported no difference in alcohol scores for the intervention group but depression scores 
were significantly lower at the six-week follow up. A group based mixed modality study 
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(James et al., 2004) reported significant reductions in alcohol use and a range of 
psychiatric outcomes at three months follow up.  Conversely, results from a study by 
Andrisano- Ruggieri et al. (2016) showed fewer positive results for the effectiveness of 
group counselling and results were hampered by a weak methodological design and poor 
presentation of findings.   
 
Computer-based CBT outcomes were similar, if not more effective than therapist-based 
CBT for a reduction in depressive symptoms and alcohol use (Agyapong et al., 2013; 
Deady et al. 2016; Kay-Lambkin et al., 2008) and a non-significant reduction in alcohol- 
related problems only (Geisner et al., 2016). However, outcomes from MI based 
intervention were not significantly different when compared to a ‘brief advice’ intervention. 
However, both groups experienced improvements in comorbid conditions. Only one study 
reported a specific integrated intervention administrating a pharmacological agent and 
psychosocial support.  Although a small sample and no control or comparison group, 
Lamotrigine and an individual relapse prevention programme demonstrated a significant 
reduction in problematic alcohol use and psychiatric symptoms.  
 
Limitations 
 
The review considered the policy frameworks and government guidelines for comorbid 
alcohol use disorders and a range of mental health disorders. This was a complex topic 
for a number of reasons, including the range of comorbid and multi-morbid conditions, 
the continuum of severity in mental health disorders and the wide variation in complex 
psychosocial modalities and pharmacological combinations used to address comorbid 
conditions. As regards the policy and service delivery review, a broad-based literature 
appraisal was undertaken to identify key documents for assessment, care planning and 
guidelines within the UK context together with a national and international review of the 
literature in relation to models of service delivery. This was not an exhaustive list and 
presented an overview of a number of the pertinent issues presented within a selection of 
the most relevant documents.  
 
Similarly, whilst the studies included in the interventions review above demonstrate a 
range of positive outcomes the results must be interpreted with a level of caution. This is 
due to identified gaps in methodological rigour and study design. Despite the majority of 
studies reporting randomised controlled trials there were a number of design flaws in the 
methodologies, for example, small samples, missing data, high attrition rate at follow up 
and lack of control comparisons. Psychosocial studies were also more likely to report 
small sample sizes and showed a higher degree of heterogeneity primarily in relation to 
mixed alcohol and drug using comorbid samples.  
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Recommendations 
 
Recommendations (Policy) 
 
1 There should be a standard definition of co-existing mental health and alcohol use                               
disorders which takes account of the myriad of complex issues associated with this 
multi-faceted diagnosis. 
2 A UK national policy framework for working with comorbid mental health and 
substance use disorders should be developed and should house a specific section on 
addressing issues of morbidities related to AuDs. 
3 It should also contain sections which are dedicated to specific assessment processes, 
care plans and a range of treatment models which are sufficiently amended to reflect 
the needs of patients/service users with complex comorbid, AuD needs.  
 
Recommendations (Practice)  
 
1 An individual who presents with a severe and enduring mental illness (SMI) should 
also be accurately assessed for the presence of a co-occurring AuD using a specific 
validated screening tool. 
2 The shunting of service users between mental health substance use disorder services 
(including AuDs) should be avoided at all costs as this serves as a significant barrier 
to timely and adequate care and support for service users, carers and family 
members.  
3 Combination drug treatments for AuDs and mental health comorbidities (specifically 
Naltrexone and Dilsulfiram within drug dyad modalities) showed positive indicators for 
alcohol and mental health outcomes; likewise psychosocial interventions which were 
largely CBT focused showed some benefits for practice. Therefore, it may be 
beneficial to include one or more of these drug combinations with CBT in future 
interventions. 
 
Recommendations (Research)  
 
1 A UK prevalence study should ascertain the number and category of service delivery 
models in the UK which address the needs of service users with concomitant AuDs 
and mental health disorders.   
2 The studies did not always demonstrate a rigorous methodological approach or 
design standard. Therefore, it is recommended that high-quality random controlled 
trials of drug combinations are conducted with adequate sample sizes and robust 
control and comparison groups. It is also recommended that further methodologically 
rigorous intervention studies are funded to investigate integrated treatment modalities 
which include pharmacological and psychosocial interventions.   
 
 
. 
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Appendix A: Example search strategy 
 
Search Strategy  
 
“Substance use” OR “substance misuse” OR “substance abuse” OR “substance 
disorder*” OR 
“alcohol use” OR “alcohol misuse” OR “alcohol abuse” OR “alcohol disorder*” OR 
“alcohol dependen*” OR alcoholi* OR korsakoffs OR “alcohol related brain disorder” 
OR “alcohol related brain injury” 
AND 
“Mental health disorder*” OR “mental illness*” OR “mental ill health” OR bipolar OR 
“personality disorder*” OR “complex need*” OR “social instability*” OR suicide* OR 
schizophrenia OR “psychiatric disorder*” OR “borderline personality disorder*” OR 
anxiety 
AND 
“Dual Diagnosis” OR “Co$morbid*”  
AND 
“Models of work*” OR “models of practice” OR “integrated model*” OR “parallel model*” 
OR “Methods of work*” OR Intervention OR “Group work” OR “Case management” OR 
“Psychosocial model*” OR “behavio* model*” OR “Motivational Interview*” OR 
“cognitive therap*” OR “cognitive behavio* therap*” OR CBT OR Naltrexone OR 
pabrinex OR  vivitrol 
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Appendix B: Quality assessment using Cochrane Risk of Bias Tool (for RCTs)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane Risk of Bias Tool (for RCTs) 
Type of bias Selection  Performance Detection Attrition Reporting 
Author            Year Random sequence generation 
Allocation 
concealment 
Blinding of 
participants 
and 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome 
data 
Selective 
reporting Other biases 
Agyapong et al., 2013 Low Low Moderate Low Moderate Low Low 
Baker et al., 2002 High High ? Low High ? High 
Brady et al., 2005 Low Low Low High High Low High 
Brown et al., 2009 Low Low High High High Low High 
Brown et al., 2011 High High High High High Low High 
Brown et al., 2014 Low Low Low Low High Low High 
Deady et al., 2016 High High Low Low high Low High 
Geisner et al., 2016 High High ? ? ? Low High 
Gual et al., 2003 High High Low High High High High 
Hernandez-Avila et al., 
2004 
Low Low High High High Low High 
James et al., 2004 Moderate Moderate High High High ? High 
Kay-Lambkin et al., 
2009 
High High ? Low Moderate ? High 
Morley et al., 2016 Moderate Moderate ? Low Low ? Low 
Toneatto & Calderwood 
2015 
High High ? ? High ? High 
Petrakis et al., 2005 High High High High High Low High 
Pettinati et al., 2005 Low Low ? ? High ? High 
Ralevski et al., 2011 High High High High High ? High 
Tolliver et al., 2012 High High High ? High ? High 
Salloum et al., 2005 Low Low Low Low Low Low High 
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Quality assessment using Evidence Project Study Risk of Bias Tool (for non-RCTs)  
 
 
Evidence project Study Risk of Bias Tool (for non-RCTs) 
Author Year 
Study design includes 
Comparison groups equivalent 
at baseline on Sampling bias 
Control for 
potential 
confounders 
Follow 
up rate 
>80% 
 
Pre-post 
intervention 
 
Control or 
comparison 
group 
No Cohort 
Socio 
demographics 
Outcome 
measures 
Random 
assignment 
(group or 
individual) to 
the 
intervention 
Participants 
randomly 
selected for 
assessment 
Andrisano-Ruggieri et al., 
2016 
Yes Yes Yes N/a N/a No No No ? 
Bogenshutz et al 2016 Yes No No N/a N/a No No No No 
Di Nicola et al., 2017 Yes Yes Yes Yes Yes No No No ? 
Martinotti et al., 2008 Yes No Yes N/a N/a No No No No 
Rubio et al., 2006 Yes No Yes N/a N/a No No No Yes 
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Appendix C: Abbreviations used in Table 2  
 
ADIS-IV: Anxiety disorders interview schedule 
AIMS: Abnormal Involuntary Movement Scale 
ALT/AST: Alanine aminotransferase test 
ASI: Addiction Severity Index 
AUDIT: Alcohol Use Disorders Identification Test 
BAI: Brief alcohol Intervention 
BARS: Barnes Akathisia Scale 
BDI-II: Becks depression Inventory-II 
BPRS: Brief psychiatric rating scale 
BRMS: Bech-Rafaelsen Mania Scale 
BSI: Brief Symptom Inventory 
CAD: Cumulative Abstinence Duration 
CAPS: Clinician Administrated PTSD Symptom Scale 
CDT: Carbohydrate-deficient transferrin test 
CG: Control group 
CGI-S: Clinical Global Impression-severity scale 
CIWA-Ar: Clinical Institute Withdrawal Assessment 
CPZ: chlorpromazine equivalent dose 
DASS-2: Depression, Anxiety and Stress Scale  
DAST: Drug abuse screening test 
DD: Drinking days 
DDQ:  Daily drinking questionnaire 
ECG: Electrocardiogram test 
EuropASI: European Addiction Severity index 
EG: Experimental group 
GGT: Gamma-glutamyl Transferase test 
HAM-A: Hamilton Anxiety Rating Scale 
HDDs: heavy drinking days 
HRSD/HAM-D: Hamilton Rating Scale for Depression  
HSCL: Hopkins Symptom checklist 
MADRS: Montgomery-Asberg Depression Rating Scale 
MALT: Munich Alcoholism Test 
MHRSD: Modified Hamilton Rating Scale for Depression 
MINI: International Neuropsychiatric Interview questionnaire 
PACS: Penn Alcohol Craving Scale 
PANSS: Positive and negative syndrome 
PHQ-9: Patient Health Questionnaire 
POLYTOT: number of substances used 
PRD-III: Psychobiology of Recovery in Depression III Somatic Symptom Scale 
PSQI: Pittsburgh Sleep Quality Index 
OTI: Opiate Treatment Index 
RAPI: Rutgers alcohol problem index  
TAC: transdermal alcohol concentration 
TLFB: Timeline Feedback score 
TOT-AL: Total alcohol drinking test  
SADS; Severity of Alcohol Dependence Scale 
SAI: State Anxiety Inventory  
SAS: Simpson-Angus Scale 
SCID-RV: Structured clinical interview for DSM  
SCL-90: Symptom checklist 90 revised 
UDS: Urine drug screening test 
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VASC: Visual Analogue Scale for Craving severity   
YMRS: Youth Mania Rating Scale 
 
 
